Giganti, Francesco http://orcid.org/0000-0001-5218-6431
Moore, Caroline M.
Robertson, Nicola L.
McCartan, Neil
Jameson, Charles
Bott, Simon R. J.
Winkler, Mathias
Gambarota, Giulio
Whitcher, Brandon
Castro, Ramiro
Emberton, Mark
Allen, Clare
Kirkham, Alex
Funding for this research was provided by:
University College London
Article History
Received: 10 January 2017
Revised: 30 March 2017
Accepted: 19 April 2017
First Online: 18 May 2017
Compliance with ethical standards
:
: The scientific guarantor of this publication is Prof. Mark Emberton.
: The authors of this manuscript declare relationships with the following companies:Mark Emberton is a UK National Institute of Health Research (NIHR) Senior Investigator. In addition, he receives research support from the UCLH/UCL NIHR Biomedical Research Centre.Ramiro Castro, MD, is a full GSK R&D employee.Alex Kirkham receives research support from the UCLH/UCL NIHR Biomedical Research Centre.
: The study was investigator-led and sponsored by University College London.The study was supported financially by GSK who also provided supplies of both drug and placebo. GSK had no input into the design, conduct and analysis of the study. The manuscript has been reviewed by GSK but final editorial control rests with the principal investigator (Mark Emberton), who serves as guarantor of the study.
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in: Moore CM, Robertson NL, Jichi F, et al (2017) The effect of dutasteride on MRI-defined prostate cancer lesions: MAPPED (Magnetic resonance imaging in Primary Prostate Cancer after Exposure to Dutasteride) – a randomized placebo-controlled, double-blind clinical trial. J Urol. 197(4):1006-1013. doi: ExternalRef removed.
: • prospective• randomised controlled trial• performed at one institution